Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654074 | 1.00 | EPHX2 (1.00) | EPHX2ALOX5 | |
| SCHEMBL14424455 | 0.94 | EPHX2 (0.88) | EPHX2 | |
| SCHEMBL12931855 | 0.90 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL12931853 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL2050549 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL2325195 | 0.88 | EPHX2 (0.97) | EPHX2 | |
| SCHEMBL14503292 | 0.87 | EPHX2 (0.77) | EPHX2 | |
| SCHEMBL12931834 | 0.86 | EPHX2 (0.82) | EPHX2ALOX5 | |
| SCHEMBL12931851 | 0.86 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL12932025 | 0.86 | EPHX2 (0.88) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-8455652-B2 | Inhibitors for the soluble epoxide hydrolase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090069418-A1 | Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326039-A1 | INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALOX5 58/4885 |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALOX5 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.